NASDAQ · Biotechnology · USD
Artelo Biosciences, Inc. (ARTL) Stock Analysis
Artelo Biosciences, Inc. (ARTL) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.
Last Updated: October 21, 2026
Price History
No price data available
Hover for the daily close. The dotted line marks the period open.
ARTL Key Statistics
As of Oct 21, 2026Trading
- Open
- $2.62
- Previous Close
- $2.62
- Day's Range
- 2.56–2.71
- 52-Week Range
- 2.56–179.19
- Volume
- 17.37K
- BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
- −0.07
Valuation
- Market Cap
- $1.40M
- P/E Ratio
- unprofitable
- EPS (ttm)Profit attributable to each share over the last twelve months.
- −136.26
Financials (FY)
- Revenue (FY)
- $0.00
- Net Income (FY)
- −$12.88M
- Shares Outstanding
- 547.77K
- 1-Year Return
- −97.25%
Dividend and dates
- Avg Volume
- 480.72K
Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.
Key facts
As of October 21, 2026, ARTL closed at $2.56, −97.25% over 1 year.
Artelo Biosciences, Inc. (ARTL) has a market capitalization of $1.40M.
In fiscal 2025, ARTL reported revenue of $0.00.
ARTL Stock Return by Calendar Year
Artelo Biosciences, Inc. (ARTL) return since Jun 2019: what $10,000 became
- 1 year
- $10,000 $275
- −97.25%
- 5 years
- $10,000 $14
- −99.86%
- Since Jun 2019
- $10,000 $2
- −99.98%
If you had invested $10,000 in Artelo Biosciences, Inc. (ARTL) at the close on June 21, 2019, the earliest close on record here, it would have been worth $2 at the close on October 21, 2026: −99.98% in total, −68.15% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.
Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.
| Year | Return |
|---|---|
| 2026 (partial year) | −92.23% |
| 2025 | −80.82% |
| 2024 | −24.29% |
| 2023 | −51.56% |
| 2022 | −62.88% |
| 2021 | −28.90% |
| 2020 | −72.96% |
| 2019 (partial year) | −41.94% |
As of October 21, 2026.
ARTL Revenue and Earnings by Fiscal Year
FY ends December| Fiscal year | Revenue | Net income | Net margin |
|---|---|---|---|
| 2025 | $0.00 | −$12.88M | — |
| 2024 | $0.00 | −$9.83M | — |
| 2023 | $0.00 | −$9.29M | — |
| 2022 | $0.00 | −$10.08M | — |
| Fiscal year | Revenue | Gross profit | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| 2025 | $0.00 | — | −$11.40M | −$12.88M | — |
| 2024 | $0.00 | — | −$10.11M | −$9.83M | — |
| 2023 | $0.00 | — | −$9.93M | −$9.29M | — |
| 2022 | $0.00 | — | −$10.29M | −$10.08M | — |
Annual figures as reported, in the company's reporting currency. As of December 31, 2025.
Recent News
Artelo Biosciences Selected for its First-Ever Company Presentation at BIO-Europe 2026 to Showcase Clinical Progress and Expanding Potential of its Novel FABP5 Inhibitor Platform
YahooArtelo Biosciences (ARTL) Stock Surges Wednesday: What's Happening?
BenzingaArtelo Biosciences Files New Provisional Patent Application Covering ART27.13 for Obesity, Alone and in Combination with GLP-1 Receptor Agonists, Following Unexpected Nonclinical Findings
YahooArtelo Biosciences Files Provisional Patent Application For ART27.13 As Monotherapy And In Combination With GLP-1 Receptor Agonists
BenzingaArtelo Cannabinoid Drug Doubles Weight Loss When Paired with Popular Obesity Drug
BenzingaArtelo Biosciences Announces ART27.13 Achieved Weight Loss Comparable to Semaglutide as a Monotherapy and Doubled Weight Loss in Combination with Semaglutide in a Nonclinical Model of Obesity
Yahoo
All 14 articles ↓Show fewer ↑
Artelo Biosciences to Present at the H.C. Wainwright 28th Annual Global Investment Conference
YahooArtelo Biosciences Announces 1-For-9 Reverse Stock Split, Effective August 31
BenzingaArtelo Biosciences Issued Notification Of Allowance From Japanese Patent Office With Decision To Grant Patent Application For Commercial Formulation Of ART27.13
BenzingaArtelo Biosciences Says USPTO Issues Notice Of Allowance For U.S. Patent Application Covering Intended Commercial Formulation Of ART27.13, Peripherally Selective Cannabinoid Agonist Currently In Phase 2 Studies
BenzingaArtelo Biosciences Q2 EPS $(0.89) Up From $(16.83) YoY
BenzingaArtelo Biosciences Says First Patient Dosed In DREAM Study Evaluating Effects Of ART27.13 In Patients With Glaucoma Or Ocular Hypertension; Initial DREAM Study Results Anticipated In Q4
BenzingaArtelo Biosciences Announces Publication Of Article 'Evaluating The Pharmacokinetics, Efficacy, And Safety Of Low Dose Cannabidiol' In The British Journal Of Clinical Pharmacology
BenzingaArtelo Biosciences Announces Oral Administration Of ART26.12 Lowers Osteoarthritis-Associated Pain Behaviors Over 4-Week Testing; Shows Efficacy To Naproxen
Benzinga
News provided by third-party sources. Not financial advice.
Analysis
Data-derivedEvery figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.
Related Biotechnology Stocks
Vertex Pharmaceuticals Incorporated
$132.95B
MRNAModerna, Inc.
$98.14B
REGNRegeneron Pharmaceuticals, Inc.
$82.95B
ARGXargenx SE
$55.97B
ONCBeOne Medicines AG
$43.97B
RVMDRevolution Medicines, Inc.
$41.64B
Popular Healthcare Stocks
Eli Lilly and Company
$1.13T
JNJJohnson & Johnson
$621.22B
ABBVAbbVie Inc.
$503.27B
UNHUnitedHealth Group Incorporated
$374.30B
MRKMerck & Co., Inc.
$369.78B